Pulse Biosciences (NASDAQ:PLSE) Issues Earnings Results, Misses Estimates By $0.01 EPS

Posted by Geri Gentry on Nov 7th, 2026

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) released its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01), Zacks reports. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.52 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Pulse Biosciences’s revenue was down 54.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) EPS.

Here are the key takeaways from Pulse Biosciences’ conference call:

Pulse completed enrollment in its NANOPULSE-AF pivotal study with 169 evaluable patients, three months ahead of its original schedule. Patients are now in follow-up, with blended six- and 12-month results expected in Q3 2027.
Preliminary PRECISE-BTN results showed that a single Vybrance treatment reduced thyroid nodule volume by more than 50% in 86% of patients, with a 78% average improvement in quality-of-life scores at six months and no serious adverse events reported. Further follow-up is due in 2027 and will support a planned 510(k) submission.
The company ended the quarter with $189.2 million in cash and marketable securities, which management says provides roughly two years of runway; about $64 million of ATM capacity remains. It plans to use capital for clinical programs and manufacturing and commercial-launch preparation.
Q3 revenue was just $395,000, while GAAP net loss widened to $23.1 million from $19.4 million a year earlier. Management expects quarterly non-GAAP costs and expenses to rise 15%–25% above the roughly $20 million average in Q2 and Q3 as clinical and pre-commercial investment increases.
Pulse is preparing manufacturing capacity and market-launch plans for its nPulse catheter, targeting launch readiness beginning in early 2028 and remaining open to a partnership or other launch structure. However, strategic discussions have not produced a disclosed deal, and management said partners are waiting for further clinical and regulatory evidence.

Pulse Biosciences Price Performance

PLSE opened at $53.29 on Friday. The firm has a market capitalization of $3.77 billion, a PE ratio of -44.04 and a beta of 1.65. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $58.90. The company’s 50-day moving average is $51.55 and its 200 day moving average is $32.28.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on PLSE shares. Oppenheimer raised their target price on shares of Pulse Biosciences from $35.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, October 13th. Needham & Company LLC upped their target price on Pulse Biosciences from $58.00 to $64.00 and gave the company a “buy” rating in a research report on Friday. Wall Street Zen cut Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Mizuho set a $65.00 target price on shares of Pulse Biosciences in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.60.

Get Our Latest Analysis on Pulse Biosciences

Insider Buying and Selling

In related news, COO Liane Teplitsky purchased 1,036 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, August 26th. The shares were acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the transaction, the chief operating officer directly owned 1,036 shares in the company, valued at $49,966.28. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 4,095 shares of company stock valued at $199,931. 74.00% of the stock is owned by insiders.

Key Stories Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.

Earnings History for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.